These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 36947792)

  • 1. Psychosocial determinants of pre-exposure prophylaxis use among pregnant adolescent girls and young women in Cape Town, South Africa: A qualitative study.
    Haribhai S; Khadka N; Mvududu R; Mashele N; Bekker LG; Gorbach P; Coates TJ; Myer L; Joseph Davey DL
    Int J STD AIDS; 2023 Jul; 34(8):548-556. PubMed ID: 36947792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A community-based mobile clinic model delivering PrEP for HIV prevention to adolescent girls and young women in Cape Town, South Africa.
    Rousseau E; Bekker LG; Julies RF; Celum C; Morton J; Johnson R; Baeten JM; O'Malley G
    BMC Health Serv Res; 2021 Aug; 21(1):888. PubMed ID: 34454505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PrEP use and HIV seroconversion rates in adolescent girls and young women from Kenya and South Africa: the POWER demonstration project.
    Celum CL; Bukusi EA; Bekker LG; Delany-Moretlwe S; Kidoguchi L; Omollo V; Rousseau E; Travill D; Morton JF; Mogaka F; O'Malley G; Barnabee G; van der Straten A; Donnell D; Parikh UM; Kudrick L; Anderson PL; Haberer JE; Wu L; Heffron R; Johnson R; Morrison S; Baeten JM;
    J Int AIDS Soc; 2022 Jul; 25(7):e25962. PubMed ID: 35822945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Barriers to Oral HIV Pre-exposure Prophylaxis (PrEP) Adherence Among Pregnant and Post-partum Women from Cape Town, South Africa.
    Beesham I; Dovel K; Mashele N; Bekker LG; Gorbach P; Coates TJ; Myer L; Joseph Davey DL
    AIDS Behav; 2022 Sep; 26(9):3079-3087. PubMed ID: 35316471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adherence, safety, and choice of the monthly dapivirine vaginal ring or oral emtricitabine plus tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis among African adolescent girls and young women: a randomised, open-label, crossover trial.
    Nair G; Celum C; Szydlo D; Brown ER; Akello CA; Nakalega R; Macdonald P; Milan G; Palanee-Phillips T; Reddy K; Tahuringana E; Muhlanga F; Nakabiito C; Bekker LG; Siziba B; Hillier SL; Baeten JM; Garcia M; Johnson S; McClure T; Levy L; Livant E; Jacobson C; Soto-Torres L; van der Straten A; Hosek S; Rooney JF; Steytler J; Bunge K; Parikh U; Hendrix C; Anderson P; Ngure K;
    Lancet HIV; 2023 Dec; 10(12):e779-e789. PubMed ID: 37898146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early pre-exposure prophylaxis (PrEP) initiation and continuation among pregnant and postpartum women in antenatal care in Cape Town, South Africa.
    Joseph Davey DL; Mvududu R; Mashele N; Lesosky M; Khadka N; Bekker LG; Gorbach P; Coates TJ; Myer L
    J Int AIDS Soc; 2022 Feb; 25(2):e25866. PubMed ID: 35138678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baseline preferences for oral pre-exposure prophylaxis (PrEP) or dapivirine intravaginal ring for HIV prevention among adolescent girls and young women in South Africa, Uganda and Zimbabwe (MTN-034/IPM-045 study).
    Ngure K; Friedland BA; Szydlo DW; Roberts ST; Garcia M; Levy L; Akello CA; Reddy K; Palanee-Phillips T; Macdonald P; Siziba B; Soto-Torres L; Hosek S; Hillier SL; Nair G; Celum C; van der Straten A
    PLoS One; 2023; 18(6):e0287525. PubMed ID: 37352296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stepped care to optimize pre-exposure prophylaxis (PrEP) effectiveness in pregnant and postpartum women (SCOPE-PP) in South Africa: a randomized control trial.
    Joseph Davey DL; Dovel K; Cleary S; Khadka N; Mashele N; Silliman M; Mvududu R; Nyemba DC; Coates TJ; Myer L
    BMC Public Health; 2022 Jul; 22(1):1306. PubMed ID: 35799121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV prevention at drug shops: awareness and attitudes among shop dispensers and young women about oral pre-exposure prophylaxis and the dapivirine ring in Shinyanga, Tanzania.
    Tubert J; Packel L; Hunter LA; Mfaume R; Njau P; Ramadhani AA; Liu JX; McCoy SI
    AIDS Res Ther; 2021 Apr; 18(1):21. PubMed ID: 33902623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Community PrEP Study: a randomized control trial leveraging community-based platforms to improve access and adherence to pre-exposure prophylaxis to prevent HIV among adolescent girls and young women in South Africa-study protocol.
    Medina-Marino A; Bezuidenhout D; Hosek S; Barnabas RV; Atujuna M; Bezuidenhout C; Ngwepe P; Peters RPH; Little F; Celum CL; Daniels J; Bekker LG
    Trials; 2021 Jul; 22(1):489. PubMed ID: 34311754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring adolescent girls and young women's PrEP-user profiles: qualitative insights into differentiated PrEP delivery platform selection and engagement in Cape Town, South Africa.
    Rousseau E; Sikkema KJ; Julies RF; Mazer K; O'Malley G; Heffron R; Morton JF; Johnson R; Celum C; Baeten JM; Bekker LG
    J Int AIDS Soc; 2024 May; 27(5):e26254. PubMed ID: 38695101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral pre-exposure prophylaxis preference, uptake, adherence and continuation among adolescent girls and young women in Kampala, Uganda: a prospective cohort study.
    Mayanja Y; Kamacooko O; Lunkuse JF; Muturi-Kioi V; Buzibye A; Omali D; Chinyenze K; Kuteesa M; Kaleebu P; Price MA
    J Int AIDS Soc; 2022 May; 25(5):e25909. PubMed ID: 35543110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mandrax use, sexual risk, and opportunities for pre-exposure prophylaxis among out-of-school adolescent girls and young women in Cape Town, South Africa.
    Bonner CP; Browne FA; Carney T; Shangase N; Ndirangu JW; Myers B; Wechsberg WM
    S Afr Med J; 2022 Apr; 112(5):341-346. PubMed ID: 35587247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stigma in the health clinic and implications for PrEP access and use by adolescent girls and young women: conflicting perspectives in South Africa.
    Nyblade L; Ndirangu JW; Speizer IS; Browne FA; Bonner CP; Minnis A; Kline TL; Ahmed K; Howard BN; Cox EN; Rinderle A; Wechsberg WM
    BMC Public Health; 2022 Oct; 22(1):1916. PubMed ID: 36242000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Uptake of and adherence to oral pre-exposure prophylaxis among adolescent girls and young women at high risk of HIV-infection in Kampala, Uganda: A qualitative study of experiences, facilitators and barriers.
    Kayesu I; Mayanja Y; Nakirijja C; Machira YW; Price M; Seeley J; Siu G
    BMC Womens Health; 2022 Nov; 22(1):440. PubMed ID: 36357920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strengthening health system's capacity for pre-exposure prophylaxis for adolescent girls and young women and adolescent boys and young men in South Africa (SHeS'Cap-PrEP): Protocol for a mixed methods study in KwaZulu-Natal, South Africa.
    Nicol E; Ramraj T; Hlongwa M; Basera W; Jama N; Lombard C; McClinton-Appollis T; Govindasamy D; Pass D; Funani N; Aheron S; Paredes-Vincent A; Drummond J; Cheyip M; Dladla S; Bedford J; Mathews C
    PLoS One; 2022; 17(3):e0264808. PubMed ID: 35298487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How a menu of adherence support strategies facilitated high adherence to HIV prevention products among adolescent girls and young women in sub-Saharan Africa: a mixed methods analysis.
    Roberts ST; Mancuso N; Williams K; Nabunya HK; Mposula H; Mugocha C; Mvinjelwa P; Garcia M; Szydlo DW; Soto-Torres L; Ngure K; Hosek S
    J Int AIDS Soc; 2023 Nov; 26(11):e26189. PubMed ID: 37936551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continued attendance in a PrEP program despite low adherence and non-protective drug levels among adolescent girls and young women in Kenya: Results from a prospective cohort study.
    Tapsoba JD; Cover J; Obong'o C; Brady M; Cressey TR; Mori K; Okomo G; Kariithi E; Obanda R; Oluoch-Madiang D; Chen YQ; Drain P; Duerr A
    PLoS Med; 2022 Sep; 19(9):e1004097. PubMed ID: 36095005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of HIV-related stigma on PrEP disclosure and adherence among adolescent girls and young women in HPTN 082: a qualitative study.
    Velloza J; Khoza N; Scorgie F; Chitukuta M; Mutero P; Mutiti K; Mangxilana N; Nobula L; Bulterys MA; Atujuna M; Hosek S; Heffron R; Bekker LG; Mgodi N; Chirenje M; Celum C; Delany-Moretlwe S;
    J Int AIDS Soc; 2020 Mar; 23(3):e25463. PubMed ID: 32144874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acceptability, safety, and patterns of use of oral tenofovir disoproxil fumarate and emtricitabine for HIV pre-exposure prophylaxis in South African adolescents: an open-label single-arm phase 2 trial.
    Gill K; Johnson L; Dietrich J; Myer L; Marcus R; Wallace M; Pidwell T; Mendel E; Fynn L; Jones K; Wiesner L; Slack C; Strode A; Spiegel H; Hosek S; Rooney J; Gray G; Bekker LG
    Lancet Child Adolesc Health; 2020 Dec; 4(12):875-883. PubMed ID: 33222803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.